Kamran Alam
Director of Finance/CFO bei TAYSHA GENE THERAPIES, INC.
Vermögen: 445 659 $ am 31.03.2024
Profil
Kamran Alam is currently the Chief Financial Officer & Secretary at Taysha Gene Therapies, Inc. Prior to this, he held positions as Finance Director at Naurex, Inc., Senior Director-Finance & Accounting at Aptinyx, Inc., Vice President-Finance at Novartis Gene Therapies, Inc., and Chief Financial Officer & Senior Vice President at Rocket Pharmaceuticals, Inc. He completed his undergraduate degree at Stephen M.
Ross School of Business and holds an MBA from Kelley School of Business.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
02.02.2024 | 155 282 ( 0,08% ) | 445 659 $ | 31.03.2024 |
Aktive Positionen von Kamran Alam
Unternehmen | Position | Beginn |
---|---|---|
TAYSHA GENE THERAPIES, INC. | Director of Finance/CFO | 01.08.2020 |
Ehemalige bekannte Positionen von Kamran Alam
Unternehmen | Position | Ende |
---|---|---|
ROCKET PHARMACEUTICALS, INC. | Director of Finance/CFO | 01.07.2020 |
AVEXIS INC | Corporate Officer/Principal | 01.10.2019 |
APTINYX | Comptroller/Controller/Auditor | 01.04.2016 |
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Corporate Officer/Principal | - |
Ausbildung von Kamran Alam
Stephen M. Ross School of Business | Undergraduate Degree |
Kelley School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
APTINYX | Health Technology |
ROCKET PHARMACEUTICALS, INC. | Health Technology |
TAYSHA GENE THERAPIES, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Naurex, Inc.
Naurex, Inc. Pharmaceuticals: MajorHealth Technology Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL. | Health Technology |
Novartis Gene Therapies, Inc.
Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |